hlaAllele	source	sourceEvent	sourceUrls	nctId	title	acronym	genderCriterium	countriesAndCities	hospitalsPerCity	treatment	treatmentApproachesDrugClass	treatmentApproachesTherapy	applicableCancerType	applicableDoid	blacklistCancerTypes	level	direction	evidenceUrls	date	description
A*02	CKB_TRIAL	A*02	http	NCT1	study1	study1	female	Netherlands(Utrecht;Groningen)	Utrecht(UMCU),Groningen(UMCG)	Nivolumab			Skin melanoma	X	Hematologic cancer;2531	A	RESPONSIVE	http		
A*02	CKB_EVIDENCE	A*02	http							Nivolumab			All cancer types	X	Hematologic cancer;2531	A	RESPONSIVE	http	2021-02-03	efficacy evidence
